Loyola University Chicago

Loyola eCommons
Master's Theses

Theses and Dissertations

2015

Malaria Transmission Blocking Vaccines
Lukasz Jacek Sewera
Loyola University Chicago

Follow this and additional works at: https://ecommons.luc.edu/luc_theses
Part of the Virology Commons

Recommended Citation
Sewera, Lukasz Jacek, "Malaria Transmission Blocking Vaccines" (2015). Master's Theses. 3149.
https://ecommons.luc.edu/luc_theses/3149

This Thesis is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It
has been accepted for inclusion in Master's Theses by an authorized administrator of Loyola eCommons. For more
information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 2015 Lukasz Jacek Sewera

LOYOLA UNIVERSITY CHICAGO

MALARIA TRANSMISSION BLOCKING VACCINES

A THESIS SUBMITTED TO
THE FACULTY OF THE GRADUATE SCHOOL
IN CANDIDACY FOR THE DEGREE OF
MASTER OF SCIENCE

PROGRAM IN MICROBIOLOGY AND IMMUNOLOGY

BY
LUKASZ SEWERA
CHICAGO, IL
DECEMBER 2015

Copyright by Lukasz Sewera, 2015
All rights reserved.

ACKNOWLEDGEMENTS
I would like to thank Dr. Chris Wiethoff for being my mentor and helping me
develop the ideas in my project. Chris has always been available to discuss new ideas and
fosters a collaborative environment in lab. I want to thank the other members of the lab
for helping me with experiments and for always being willing to show me new
techniques. All the members of our lab made my experience in graduate school much
more enjoyable. I would also like to thank the members of my thesis committee for
providing feedback on my project and helping me stay on track. The environment in the
Department of Microbiology and Immunology has been very supportive and I want to
thank everyone in the department. I want to thank my family and friends for their support
throughout my education. They have always been around to provide valuable advice and
support.

iii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS

iii

LIST OF FIGURES

vi

ABSTRACT

vii

CHAPTER ONE: REVIEW OF LITERATURE
Malaria: epidemiology
Malaria: lifecycle and disease
Malaria: host response
Malaria: current treatments
Malaria: approaches to eradication
Malaria: vaccine development
Malaria: transmission blocking vaccines
Pfs25
Pfs25: structure
Antibody response to vaccines
Vaccine adjuvants
Adenovirus
Adenovirus vaccine vectors
Improving Ad vectors for TBV

1
1
3
6
7
8
10
13
14
15
19
21
23
24
26

CHAPTER TWO: MATERIALS AND METHODS
Cell lines and cell culture
Recombinant virus construction
Virus purification and titering
Reagents and antibodies
ELISA
Mice and immunizations
Pfs25 domain synthesis and purification
SDS-PAGE and Western blots
Statistics

27
27
27
28
29
29
30
31
33
34

CHAPTER THREE: RESULTS
EGF domain expression
Refolding of domains from Pfs25
Pfs25 expression by cells infected with Ad5Pfs25exo

35
35
38
42

iv

Antibody response to immunization with Ad5Pfs25exo
Domain specific antibody response to immunization with Ad5Pfs25exo
Domain specific antibody response to AdCD vectors
Transmission blocking activity of serum from mice immunized with AdCD
A new epitope from domain 3
Antibody response to AdCD vectors with FliC

44
46
48
50
52
54

CHAPTER FOUR: DISCUSSION
Refolding of Pfs25 domain 3
Domain specific ELISA
Creating new AdCD vectors
Focusing the antibody response to transmission blocking epitopes
Effect of capsid displayed FliC on antibody response to AdCD vectors
Concluding remarks

57
57
59
60
61
62
63

REFERENCES

65

VITA

77

v

LIST OF FIGURES

Figure

Page

1.

Global distribution of malaria

2

2.

Plasmodium falciparum lifecycle

5

3.

Pfs25 protein model

17

4.

Domain 3 expression in E. coli

35

5.

Purified domain 3 protein gel

38

6.

ELISA titers to domain 3 using ID2 and 4B7

39

7.

Expression of Ad5Pfs25exo by 293β5 cells

41

8.

Anti-Pfs25 ELISA titers for Ad5Pfs25exo

43

9.

Domain specific ELISA titers for Ad5Pfs25exo and Ad5Pfs25

45

10.

Domain specific ELISA titers for AdCD

47

11.

SMFA with Ad5Pfs25/Pfs25-alum and Ad5Pfs25/AdCD

49

12.

ELISA titers to new capsid displayed antigen D3C

51

13.

Anti-Pfs25 ELISA titers for AdCD PF

53

14.

Anti-capsid ELISA titers for AdCD PF

54

vi

ABSTRACT
Malaria affects 198 million people and kills 584,000 each year, predominantly in
Sub-Saharan Africa (WHO). The most severe form of malaria is caused by the protozoan
parasite Plasmodium falciparum. Development of a vaccine against P. falciparum has
been hindered by its complex life cycle with multiple antigenically distinct human and
mosquito stages. To effectively prevent disease and reduce the parasite burden in
populations, a vaccine will need to target multiple stages, including blocking
transmission at the mosquito stage.
Antibodies generated against P. falciparum mosquito stage antigen Pfs25 can
prevent parasite transmission from humans to mosquitoes. However, Pfs25 is poorly
immunogenic and immunization with the protein with alum as an adjuvant does not
provide adequate transmission blocking activity. In this study I used adenovirus vectors
(Ad) modified to express Pfs25 as a transgene or with capsid displayed Pfs25 epitopes to
elicit a stronger anti-Pfs25 antibody response specifically directed at epitopes highly
associated with transmission blocking.
Although antibody titers are closely associated with transmission blocking
activity, it is unlikely that all antibodies generated by immunization with whole protein
are transmission blocking. Based on molecular models, EGF-like domains 2 and 3 appear
to be most surface accessible on the parasite surface. However, antibodies raised against
soluble Pfs25 equally recognize all 4 EGF-like domains. Thus, a vaccine involving in situ
vii

expression of membrane anchored Pfs25 may better target antibody responses to domains
2 and 3. Additionally, using secondary immunization with capsid displayed Pfs25, I
expected to further direct the antibody response to predicted B cell epitopes. Serum from
mice immunized with these vectors can provide transmission blocking activity with lower
antibody titers.
Innate immune responses to Ad are an important component of generating
adaptive immunity and may provide a means to further augment antibody responses to
poorly immunogenic protein antigens. Molecules such as Pseudomonas aeruginosa
flagellin (FliC) potently activate the innate immune system and could be used to modify
vectors to induce greater adaptive immunity. We have generated Ad vectors with FliC
attached to protein IX. Using these vectors with capsid displayed Pfs25 epitopes I
assessed whether capsid displayed FliC increases antibody titers to Pfs25.
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CHAPTER ONE
REVIEW OF LITERATURE
Malaria: epidemiology
Malaria is a mosquito borne illness caused by protozoan parasites in the genus
Plasmodium. According to the 2014 World Malaria Report, 198 million cases and
584,000 deaths as a result of malaria were recorded in 97 countries. 90% of deaths were
in Africa. Worldwide, approximately 3.3 billion people are at risk of malaria and 1.2
billion are at high risk (Figure 1). However, since 2000, prevalence of malaria and deaths
due to malaria have decreased despite population growth in malaria endemic areas. This
decrease has been due to aggressive efforts to prevent parasite transmission and ongoing
efforts are necessary to maintain this trend (WHO).

1
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Figure 1: Global incidence of malaria in 2013. Most cases of malaria are concentrated in
Sub-Saharan Africa.
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Malaria: lifecycle and disease
Malaria is caused by multiple Plasmodium spp, however, P. falciparum causes the
most severe and life threatening illness and is responsible for 90% of mortality due to
malaria (Snow 2015). The lifecycle of P. falciparum is complex and involves several
antigenically and morphologically distinct stages. Sporozoites are the infectious stage of
Plasmodium spp. and are transmitted by Anopheles spp. mosquitoes. While the mosquito
feeds on its host, sporozoites in the salivary glands enter the bloodstream and travel to the
liver. After invading hepatocytes, sporozoites divide many times to form schizonts.
Schizonts contain thousands of merozoites, which enter the bloodstream when schizonts
rupture 6 to 30 days post infection. Circulating merozoites invade red blood cells (RBC)
and undergo maturation to schizonts over 48 hours. Infection of RBC causes multiple
morphologic changes that lead to increased splenic clearance of RBC and anemia.
Structural changes in the RBC surface can also lead to obstruction of small vessels which
is especially problematic in the kidney and brain. After maturation is complete, schizonts
rupture and RBC lyse, releasing merozoites that can then infect new cells. RBC lysis
releases cell membrane remnants and hemoglobin degradation products, which are
phagocytosed by macrophages and can also activate endothelial cells. This activation of
immune cascades leads to release of pro-inflammatory cytokines, which suppress
hematopoiesis and exacerbate anemia that results from parasite induced splenic clearance
of RBC (McDevitt et al. 2004).
While the majority of merozoites undergo this asexual cycle, some differentiate
into male and female gametocytes and undergo a 3-4 day maturation process after which
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they are released into the blood. Gametocytes make up only 1.8-5.7% of total parasitemia
in blood (Ouedraogo et al. 2010). Mature gametocytes circulate in the bloodstream and
can be ingested by a feeding mosquito. In the mosquito midgut, pH, temperature change
and xanthurenic acid cause gametocytes to differentiate into male and female
gametocytes. Male and female gametocytes mate to produce zygotes which develop into
ookinetes and penetrate the gut wall. Ookinetes become oocysts, which eventually release
sporozoites. Sporozoites migrate to the salivary glands and can initiate a new cycle of
infection when the mosquito feeds on a new host (Leroy et al. 2014).
The initial incubation stage of malaria is asymptomatic and lasts 12-14 days for P.
falciparum. The incubation period can last longer due to partial immunity or ineffective
prophylaxis (Schwartz et al. 2003). Symptoms occur during the erythrocytic stage and are
a result of RBC lysis and release of pro inflammatory cytokines. Malaria begins with
non-specific symptoms such as fever, malaise and fatigue. When merozoites are present
in the serum, they can be visualized by microscopy of blood smears. In some cases
malaria can become severe, especially with P. falciparum. Severe malaria often results
from vascular occlusion by infected RBC and can include organ failure and cerebral
malaria (WHO: Severe Malaria).

5

Figure 2: Lifecycle of Plasmodium falciparum. The lifecycle consists of human and
malaria stages and each stage is antigenically distinct. Sexual reproduction occurs in the
mosquito and asexual stages occur in humans. When a mosquito feeds on a host, it injects
sporozoites that migrate to the liver and infect hepatocytes. After reproducing in
hepatocytes to form schizonts, parasites emerge as merozoites and infect RBC. Most
parasites undergo asexual reproduction, but a small fraction differentiate into male and
female gametocytes. Gametocytes can be taken up by a mosquito during a blood meal
and in the mosquito midgut they differentiate into gametes. Gametes fuse to form
zygotes, which begin to invade the midgut wall and develop into oocysts. In the midgut
wall, parasites multiply to form sporozoites which travel to the salivary glands where
they are ready to initiate a new cycle of infection.
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Malaria: host response
Partial immunity to P. falciparum occurs in endemic areas following multiple
infections. In areas of high transmission such as sub-Saharan Africa people develop
almost complete protection from clinical disease by early adulthood. This delayed
development of immunity leaves children and pregnant women at greatest risk for
complicated disease (Langhorne et al. 2008). Immunity to severe clinical disease requires
persistent stimulation by parasite antigens, wanes when individuals leave endemic areas
and does not develop in areas of low transmission (Gupta et al. 1999). Natural malaria
infections suppress B cell memory development, which leads to short lived antibody
responses after infection, and P. falciparum induces expression of CD4+ T cell inhibitory
factors (Hviid 2007, Kinyanjui et al. 2009, Anders 1986, Butler et al. 2012)
Lifecycle stages are antigenically distinct from each other and immunity to one
stage does not provide protection from other stages. Naturally acquired immune
responses to malaria are mostly directed against blood stages including merozoites as
well as intra-erythrocyte stages. Based on passive transfer experiments, antibodies are the
major component of this protection and are involved in blocking merozoite invasion of
RBC, antibody dependent cellular killing and surface bound antibodies leading to
increased clearance of infected RBC (Blackman et al. 1990, Bouharoun-Tayoun et al.
1995 and Bull et al. 1998).
Host immune responses also play a role in the pathology associated with malaria.
TNF is protective (Taverne 1987) but high levels of TNF and other proinflammatory
cytokines are associated with severe disease (Ochiel et al. 2005). IL-10 dysregulation also
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plays a role and low IL-10 responses are associated with severe anemia, while
abnormally high IL-10 responses are associated with respiratory distress (Kurtzhals et al.
1998, Awandare et al. 2006).
Malaria: current treatments
Treatment of malaria depends on a variety of factors including species, prior
exposure, severity of disease and geographic location. Naïve patients are often
hospitalized, whereas partially immune patients don’t always require hospitalization.
During treatment, parasitemia is monitored using daily blood smears.
One of the major disadvantages of early synthetic anti-malarial drugs is that they
only target erythrocytic stages, which are the most abundant and metabolically active.
High parasite density and high mutation rates due to rapid metabolic activity increase the
likelihood of drug resistance among erythrocytic stages compared to other life cycle
stages that are less abundant and mutation prone (Fidock 2013). Drugs that only inhibit
erythrocytic stages may not effectively inhibit transmission to mosquitoes by blocking
asexual forms of P. falciparum, allowing the life cycle to continue (Leroy et al. 2014).
Chloroquine was the first mass produced drug for malaria treatment and
prevention and is effective against all blood stages, additionally, it is well tolerated if
administered orally (White 1996, Taylor and White 2004). Although chloroquine is still
used to treat other forms of malaria, P. falciparum has developed widespread resistance,
and chloroquine often cannot be used to treat falciparum malaria.
The WHO recommends oral artemisinin combination therapy (ACT) as the first
line treatment for uncomplicated falciparum malaria due to efficacy against all asexual

8
stages of the parasite lifecycle as well as gametocytes and minimal side effects. A second
drug is administered with artemisinin derivatives to reduce resistance. Severe falciparum
malaria is treated with i.v. administration of artemisinin or quinine. Artemisinins are
preferable due to broader targeting of parasite life cycle stages and a more favorable side
effect profile (ter Kuile et al. 1993).
Drug resistance varies between regions and should be considered when selecting
therapy. Artemisinin resistance has been noted in areas where monotherapy was applied
instead of using ACT (Das et al. 2013). Artemisinin resistance is particularly concerning
because of the drug’s efficacy against multiple lifecycle stages and ability to block
transmission by also targeting gametocytes. Quinine is used in areas where resistance to
other drugs may be a problem but is not the preferred treatment due to severe side effects
and bitter taste, which reduces compliance. Resistance has been documented for all
currently used antimalarials and this threat has accelerated the need to develop newer
methods of treatment and prevention (Leroy et al. 2014).
Malaria: approaches to eradication
After World War II, DDT and chloroquine were first implemented, which led to
decreased global distribution of Plasmodium falciparum and P. vivax. By the 1960’s it
became apparent that insecticides and mass drug administration would not be sufficient to
completely eliminate malaria (Dobson et al. 2000). This led to decreased interest in
continuing mass eradication efforts and a resurgence in incidence and mortality (Cohen et
al. 2012). The malaria epidemic in the 1990s in Africa (Snow et al. 2012) resulted in the
development of a new elimination strategy in 2000 called the Roll Back Malaria Global
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Action Plan (GMAP). Newer efforts have taken into account the heterogeneity of
Plasmodium spp. and focused on interrupting transmission instead of just control (Alonso
et al. 2011). Unlike previous efforts, which often bypassed local health systems, recent
efforts have focused on long term solutions by integrating malaria control efforts into
local health systems (Alonso et al. 2011).
Vector control is an important aspect of the malaria eradication program and
methods such as insecticide treated nets (ITN) are particularly effective because they kill
vectors before they become infectious, a process that takes several days after ingesting
Plasmodium spp. (Enayati and Hemingway 2010). Use of insecticide treated nets has
been widespread since 2006 but transmission rates remain high and mathematical models
show that ITNs might not be adequate to reduce transmission in highly endemic areas
(Noor et al. 2014, Griffin et al. 2010, Smith et al. 2009). In addition to drug resistance in
parasites, mosquitoes have been developing resistance to insecticides, which requires
developing new insecticides to maintain efficacy (Ranson et al. 2009). Additionally, not
all vectors feed indoors and therefore may not be susceptible to ITN. As an alternative
approach, genetic control programs have been proposed to reduce natural populations of
these vectors (malERA 2011, Terenius et al. 2008 and Sinkins and Gould 2006).
New approaches to developing antimalarials have focused on targeting multiple
life cycle stages to eliminate parasites and according to the Medicines for Malaria
Venture should cure disease by rapidly clearing parasites from the blood, target liver
stages and block transmission by targeting asexual blood stages and be effective in a
single dose (Leroy et al. 2014).
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Targeting hepatic stages would have the advantage of preventing infection by
blocking the first stage of the parasites lifecycle in humans and would prevent
transmission by preventing formation of gametocytes, additionally, the low density of
parasites during hepatic stages would reduce the likelihood of resistance compared to
drugs that target erythrocytic stages (Lindner et al. 2012). Unfortunately, studying liver
stages is difficult due to the low parasite load and no efficient high throughput liver stage
drug screens exist (Leroy et al. 2014).
Blocking parasite transmission is considered critical for eradication of malaria
(Sinden et al. 2012). Therapies that block transmission should target gametocyte
formation to prevent sexual stages from being ingested by mosquitoes. Several drugs to
target sexual stages have been identified, including primaquine, which is in clinical use
(White et al. 2012, Tanaka et al. 2013). The current method for assessing transmission
blocking activity is the standard membrane feeding assay, where mosquitoes are fed
serum containing gametocytes and candidate drugs and progression to oocysts is
determined (Leroy et al. 2014).
Malaria: vaccine development
Vaccines are an important component of the malaria eradication plan and would
be especially beneficial for children in highly endemic countries who have not yet
developed immunity (Alonso 2011). Evidence of resistance to clinical disease after
multiple exposures and the ability of transferred IgG to protect naïve humans against
disease indicate that a vaccine against malaria is possible and that antibodies can reduce
disease (Schwartz et al. 2011). However, these responses are transient and prevent
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clinical disease but do not completely prevent infection in endemic settings (Schwartz et
al. 2011). The major challenge to developing a vaccine for P. falciparum are its multiple
antigenically distinct lifecycle stages with several amplification phases. Natural immunity
is not well understood at the molecular level and few target antigens have been identified
(Moorthy and Kieny 2010).
According to the malaria eradication agenda developed in 2009-2010, effective
eradication of malaria requires a focus on preventing transmission more than preventing
morbidity (Schwartz et al. 2011). This includes vaccines that target pre-erythrocytic
stages and therefore provide sterilizing immunity as well as vaccines that target sexual
stages and mosquito antigens. However, the latter two have received the least amount of
attention (Schwartz et al. 2011). Transmission blocking vaccines (TBV) target sexual and
mosquito stages of P. falciparum (malERA 2011). The broader category of vaccines that
interrupt transmission also includes vaccines against mosquito proteins that are essential
for parasite development and highly effective erythrocyte vaccines that would also
effectively prevent transmission (Alonso 2011).
Naturally acquired immunity to P. falciparum may not be due to immune
responses to pre-erythrocytic stages but immunization with pre-erythrocytic targets can
induce protective immunity. This indicates that the immunity generated by preerythrocytic vaccines would not mimic natural immunity but it may be more effective
(malERA 2011). Pre-erythrocytic stage vaccines would prevent sporozoite invasion of
hepatocytes or activate cellular immune responses to kill infected hepatocytes. If
completely effective, this would eliminate parasites before they could infect erythrocytes
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and prevent both disease and transmission. Even a partial reduction in parasites that leave
the liver would reduce the severity of disease and could allow more time for the infected
host to develop responses against later stages (Schwartz et al. 2011).
Irradiated sporozoites inoculated by mosquito bite prevent infection upon
experimental challenge, but this requires hundreds of bites and is transient (Cochrane et
al. 1980, Clyde et al. 1973). Similar results were found using purified irradiated
sporozoites, where high doses were required and did not provide adequate protection
(Epstein et al. 2011, Daubenberger 2011). Another approach to induce immunity using
whole parasites is chloroquine controlled infection, where infected mosquitoes bite
people in the presence of chloroquine. This results in high levels of effector memory, less
suppression of T cells and only requires 10-15 bites (Butler et al. 2012, Roestenberg et al.
2011). However, drug resistance would reduce the utility of this approach (Schuldt and
Amalfitano 2012). Additionally, storing whole sporozoites presents a challenge for using
a sporozoite based vaccine in the field (Epstein et al. 2011).
The most successful malaria vaccine candidate has been RTS,S produced by GSK
and the PATH Malaria Vaccine Initiative. RTS,S is 80% effective, has completed Phase 3
clinical trials and may receive WHO approval by the end of 2015. RTS,S is directed
against the circumsporozoite protein, which is the most abundant surface antigen on
sporozoites and liver stages and the vaccine can induce antibody and CD4+ T cell
immunity. RTS,S is a fusion between CSP and hepatitis B surface antigen. In an effort to
develop CD8+ responses to CSP, clinical trials are ongoing to boost immunize RTS,S
immunized individuals with Ad35 encoding CSP (WHO 2010). Attempts to develop a
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pre-erythrocytic vaccine using whole parasite have not been successful due to the large
numbers of parasites needed for efficacy and stability concerns (Schwartz et al. 2011).
Although naturally acquired immunity appears to be primarily due to targeting
blood stages, developing a broadly effective blood stage vaccine is difficult due to
antigenic polymorphism (Colling and Jeffery 1999). Merozoite surface protein 1 is a well
characterized protein used by merozoites for invasion and antibodies against MSP-1
reduce clinical malaria (Holder 2009, Fowkes et al. 2010). All studies use portions of
MSP-1 due to its large size, which makes identification of critical epitopes important.
Results using MSP-1 have been mixed due to allelic variation in the protein and have
shown high immunogenicity but strain specific responses (Ogutu et al. 2009). Antibody
titers to MSP3 have the most consistent association with protection from clinical malaria
(Fowkes et al. 2010). Synthetic MSP3 peptide generates high antibody titers, but only in
naïve individuals (Audran et al. 2005, Sirima et al. 2007, Nebie et al. 2009). Apical
Membrane Antigen 1 is expressed on merozoites, sporozoites and hepatic stages and
antibodies to AMA1 are major component of natural immunity (Courtin et al. 2009,
Udhayakumar et al. 2001). However, AMA1 is highly polymorphic and developing a
successful AMA1 vaccine would need to overcome this (Takala and Plowe 2009).
Malaria: transmission blocking vaccines
The importance of TBV has increased as a result of poor efficacy of most blood
stage vaccine candidates in trials and the emphasis on reducing transmission as a means
to eradicate malaria (Schwartz et al. 2011). Transmission blocking vaccines can target
sexual stages of Plasmodium or mosquito vector antigens. Currently most sexual stage
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vaccine projects are in preclinical stages (Schwartz et al. 2011). As of 2012, 24 proteins
have been identified as targets of transmission blocking antibodies. There are four lead
candidates: Pfs48/45 and Pfs230 are present on gametes and gametocytes and Pfs25 and
Pfs28 are present on ookinetes (Sinden et al. 2012). The mosquito protein APN1 has also
been the focus of some studies.
One particular challenge for developing a TBV is that unlike blood stage or preerythrocytic vaccines, a TBV would act at the community level rather than the individual
level (Nunes et al 2014). However, over time this would translate to individual benefit by
reducing disease in communities where vaccine recipients live and reduce the risk of reinfection (PATH 2010). Additionally, primaquine is sometimes administered to infected
patients to prevent transmission with no expectation of clinical benefit to the patient
(WHO, Eziefula et al. 2014). Preliminary assessments of community acceptance of TBV
shows that people in affected communities are open to these interventions (Bingham et al.
2012, Ojakaa et al. 2011).
Pfs25
Pfs25 is the most studied sexual stage antigen. It is present primarily on ookinetes
and is involved in invasion of the midgut wall. Anti Pfs25 antibody titers consistently
correlate with transmission blocking activity by SMFA (Vuola et al. 2005). In this
approach, a mosquito that feeds on an infected individual who has been immunized will
take up gametocytes as well as anti-Pfs25. When Pfs25 is expressed in the mosquito
midgut, antibodies bind to Pfs25 and block invasion of the midgut wall. Compared to
other sexual stage antigens, serum from mice immunized with Pfs25 contains similar

15
levels of sexual stage antigen specific antibody titers but is significantly more effective at
blocking transmission (Miura et al. 2013).
Pfs25 administered with aluminum hydroxide (alum) as an adjuvant generates low
antibody titers in mice and must be administered multiple times to block parasite
transmission (Kubler-Kielb et al. 2006). Using various adjuvants, researchers have tried
to improve the immunogenicity of Pfs25. A clinical study using Pfs25 adjuvanted with
Montanide ISA 51 was discontinued due to low levels of antibody titers and adjuvant
toxicity (Wu et al. 2008). A Pfs25 Pseudomonas aeruginosa ExoProtein A (EPA)
conjugate with alum as an adjuvant has shown induction of high antibody titers and
transmission blocking activity but this requires 3 injections (Qian et al. 2008, Qian et al.
2007). Viral vectored approaches have also been investigated for Pfs25 immunization and
a heterologous prime-boost with Ad5 and MVA induces a strong transmission blocking
antibody response (Goodman et al. 2011). Cholera toxin and Neisseria menigitides outer
membrane protein have also been investigated as adjuvants for Pfs25 (Arakawa et al.
2005 and Wu et al. 2006).
Pfs25: Structure
Pfs25 is a 25kDa protein composed of 4 epidermal growth factor (EGF) like
domains. It is expressed on the surface of ookinetes. The N terminal portion contains a
membrane secretion signal sequence and the C terminal portion has a GPI anchor
sequence. Pfs25 is a cysteine rich protein and contains 11 disulfide bonds (Kaslow et
al.1988 and Saxena et al. 2006). The protein has multiple surface exposed loops, which
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are most prominent in EGF-like domain 2 and 3 and contain the most likely predicted B
cell epitopes (Figure 1).
Pfs25 has been expressed in a variety of systems such as yeast, cell free
translation in wheat germ, plants and algae (Barr et al. 1991, Kaslow and Shiloach 1994,
Tsuboi et al. 2008, Farrance et al. 2011 and Gregory et al. 2012). Proper folding of Pfs25
in ectopic expression systems is difficult due to its complex structure. Yeast expressed
Pfs25 consists of two isoforms, which could reduce the efficacy of immunization with
this recombinant protein (Tsai et al. 2006 and Kubler-Kielb et al. 2007). Expression in E.
coli is complicated by ineffective formation of disulfide bonds in bacterial cells. All 11
disulfide bonds in Pfs25 are necessary for proper folding and misfolded proteins must be
solubilized and refolded to generate the appropriate arrangement of disulfide bonds
(Kaslow et al. 1994). A successful purification and refolding of Pfs25 in the correct
conformation has been described by Kumar et al. 2014.
The cytoplasm in E. coli may contain proteases that could interfere with protein
isolation and to address this strains such as BL21 have been developed, which lack ompT
and lon proteases. Recombinant proteins expressed in E. coli often do not fold properly
and require additional steps to refold them. Folding of disulfide bond containing proteins
is particularly error prone in E. coli because of the reducing environment in the
cytoplasm, which prevents disulfide bond formation (Sorensen and Mortensen 2005). The
advantages of E. coli are that it is a well characterized expression system and high yields
of protein can be collected from bacterial cultures. Despite the limitations on expressing

17
correctly folded disulfide bond containing proteins, multiple EGF like proteins have been
refolded in vitro after expression in E. coli, including Pfs25.

18

Figure 3: Structure of Pfs25 modeled on the crystal structure solved for the related sexual
stage antigen from Plasmodium vivax, Pvs25. Loops containing predicted B cell epitopes
in domains 2 and 3 are highlighted in red.
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Antibody response to vaccines
After injection, antigen either diffuses to draining lymph nodes, or it can be
internalized by DC at the site of injection and transported to lymph nodes. Proteins that
encounter antigen specific naïve B cells bind to surface IgM and trigger a cascade that
leads to formation of germinal centers where they proliferate and differentiate into
plasma cells or memory B cells with help from APC and T cells.
Activated B cells can proceed down the extrafollicular pathway, which leads to a
rapid but short lived and low affinity antibody response or they can form germinal centers
leading to memory formation. The germinal center pathway is more important for
vaccine efficacy. The germinal center pathway begins when activated B and T cells
migrate to B cell follicles as a result of signaling by FDC. In follicles, B cells receive
signals from FDC and T cells and proliferate. During proliferation, they undergo class
switch proliferation and switch from IgM production to IgG, IgA or IgE. They also
undergo affinity maturation. High affinity B cells display vaccine antigens in MHCII and
are bound by antigen specific TFH cells, which provide costimulatory molecules and leads
to proliferation of B cells and differentiation to memory B cells or plasma cells. This
process requires 10-14 days before hypermutated IgG appears in serum (Flehmig et al.
1997).
The antibody response to antigen depends on several factors. Intrinsic antigenicity
of proteins is the main determinant of antibody response and is highly variable (Siegrist
2011). Live vaccines elicit the strongest antibody responses because they are better at
stimulating innate immune responses and non-live vaccines usually require at least two
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vaccine doses (Pashine et al. 2005, Cassidy et al. 2001, VanDerWielen et al. 2000). Host
factors also play a role in vaccine efficacy and genetic variability can affect the antibody
response (Newport et al. 2004). Antigen dose is an important consideration and lower
doses favor production of memory cells, while higher doses favor production of plasma
cells (Ahman et al. 1999).
The number of long lived plasma cells determines the duration of antibody
secretion after immunization and becomes apparent after 6-12 months when the short
lived plasma cell response wanes (Honorati et al. 1999, VanHerck et al. 2000). Long
lived plasma cells form from GC plasma cells that migrate to the bone marrow as a result
of signaling by bone marrow stromal cells (Minges Wols et al. 2002). Although the exact
mechanism for LLPC formation and persistence is unknown, only live attenuated viral
vaccines can induce antibody titers that persist for decades without requiring boost
immunization (Manz et al. 2005). Memory B cells do not secrete antibody, therefore they
are not protective unless they are stimulated by antigen to differentiate into plasma cells.
However, antigen stimulation of memory B cells, such as during boost immunization,
drives proliferation into plasma cells with higher affinity antibodies than those generated
by primary immunization (McHeyzer-Williams and McHeyzer-Williams 2005).
In the context of TBV, persistent antibody secretion is necessary as Pfs25 is not
expressed in human stages and a previously immunized infected person would not be reexposed to antigen. As a result, low dose primary immunization to elicit a high memory
response followed by a high dose boost immunization to elicit high levels of high affinity

21
plasma cells would be an effective strategy that could generate more LLPC and persistent
antibody titers.
Vaccine Adjuvants
Adjuvants are compounds that enhance the immune response against a coadministered target antigen (Petrovsky and Aguilar 2004). Despite adjuvants being used
in vaccines since the 1920’s, few adjuvants are licensed for clinical use due to limited
knowledge of mechanisms of action (De Gregorio et al. 2013). Since adjuvants are used
to improve immune responses, they may also be associated with toxicity due to overactivation of immune pathways and the balance of potency and toxicity is an important
consideration when developing adjuvants (Petrovsky and Aguilar 2004).
Aluminum salts (alum) were one of the first adjuvants used, with published
reports of alum as early as 1926 (Glenny et al. 1926). Alum adjuvants are used in
multiple vaccines including diphtheria, tetanus, pertussis, hepatitis A and B and anthrax
(DeGregorio et al. 2013). When formulated with alum, antigens are adsorbed to the
adjuvant, which can increase antigen stability and increases uptake of antigen by APC
(Hem and White 1995, Flach et al. 2011). Alum also increases activation of DC and other
immune effector cells (Sokolovska et al. 2007, Kool et al. 2008, Seubert et al. 2008).
Alum activates the NLRP3 inflammasome, which is required for its adjuvant effect, but
does not signal through TLR (Gavin et al. 2006, Eisenbarth et al. 2008, Kool et al. 2008).
Additionally, alum induces release of DAMP’s such as uric acid and dsDNA, which
contributes to its pro-inflammatory effect (Kool et al. 2008, McKee et al. 2013, Marichal
et al. 2011).
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Freund’s complete adjuvant is an emulsion of water, mineral oil and killed
mycobacteria and is the gold standard adjuvant, although it is too toxic for human use due
to severe local reactions (Freund et al. 1937, Petrovsky and Aguilar 2004). Oil-in water
emulsion adjuvants such as MF59 and AS03 are used in influenza vaccines. These
adjuvants are a mix of squalene and surfactants with uniform sized 160nm particles
(DeGregorio et al. 2013). MF59 does not directly activate monocytes but it stimulates
them to produce chemokines and promotes antigen uptake by APC (Dupuis et al. 2001).
Unlike alum, MF50 does not activate the Nlrp3 inflammasome (Seubert et al. 2011).
AS03 also triggers innate responses in draining lymph nodes due to the presence of
alpha-tocopherol (Garcon et al. 2012).
TLR agonists are a broad class of adjuvants that target PRR of the innate immune
system and include dsRNA, ssRNA, CpG motifs, lipids, lipopeptides, bacterial cell wall
components and flagellin (De Gregorio et al. 2013). TLR4 agonists such as MPL mimic
the activity of LPS and are found in hepatitis B and HPV vaccines (Casella and Mitchell
2008). TLR4 agonists enhance antibody responses and Th1 helper T cell responses
(Didierlaurent et al. 2009). TLR9 is found on endosomes and recognizes DNA containing
CpG, which is usually found in bacteria. TLR9 agonists can elicit different immune
responses depending on the type of CpG motifs (Vollmer et al. 2004). Bacterial flagellin
is recognized by TLR5. Since flagellin is a protein, it can be used to create fusion
proteins with target antigen (Taylor et al. 2011). Flagellin has been successfully used in
multiple vaccines to induce strong humoral responses and can increase transport and
retention of antigen in lymph nodes (Sixt et al. 2005). The effects of flagellin are most
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likely mediated by T cells and DC and it does not appear to signal directly through B
cells (Mizel and Bates 2010). Viral RNA or synthetic RNA mimics stimulate TLR7 and
TLR8 on endosomes (Akira and Hemmi 2003). TLR3 recognizes dsRNA and is the target
of adjuvants such as Poly(I:C) (Jasani et al. 2009).
Viral vectors have also been investigated as adjuvants because of their strong
ability to stimulate innate and adaptive immune responses. In particular adenovirus has
been shown to trigger strong adaptive immune responses to antigens from multiple
pathogens. Ad vectors can deliver large transgenes and can also accommodate antigenic
epitopes in their capsid.
Adenovirus
Adenoviruses are non-enveloped double stranded DNA viruses. Their 34-43kb
genome is small enough to enable easy manipulation and large parts of the genome can
be replaced. Ad are divided into serotypes based on antibody neutralization and six
subgroups based on sequence homology and red blood cell agglutination (Tatsis and Ertl
2004). Ad5, of subgroup C, is the most commonly studied of at least 52 human serotypes
of Ad (Schuldt and Amalfitano 2012).
The Ad genome is divided into early and late genes based on their expression.
E1A is involved in activation of other viral genes, therefore deleting this gene results in
replication defective virus and can be replaced with a transgene for expression by
recombinant virus (Anderson et al. 2000, He et al. 1998). The E3 gene product allows Ad
to persist in lymphoid cells after acute infection and is also often removed (Tatsis and
Ertl 2004).
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In immunocompetent hosts, human Ad cause mild upper respiratory or
gastrointestinal disease. The surface exposed portion of hexon, the major capsid protein,
contains flexible loops that are variable between serotypes and are the target of
neutralizing antibodies (Tatsis and Ertl 2004). Neutralizing antibody titers to common
serotypes such as Ad5 can be detected in up to 80% of some adult populatitons,
indicating prior infection in these individuals (Tatsis and Ertl 2004). Ad potently activate
the innate and adaptive immune responses. By expressing PAMPs, they stimulate
production of cytokines and differentiation of antigen presenting cells (Tatsis and Ertl
2004).
Adenovirus vaccine vectors
Adenoviral vectors were originally proposed as gene therapy vectors, however,
adaptive and innate immune responses to these vectors limited their utility for gene
therapy. Ad vectors are useful as vaccine adjuvants for multiple reasons, including ease
of propagation, mild disease in immunocompetent hosts and broad tropism (Tatsis and
Ertl 2004). Although multiple viral vectors have been considered for use in malaria
vaccines, only Ad and MVA have made it to clinical trials (Schuldt and Amalfitano
2012).
Ad have been useful as vaccine vectors due to their ability to stimulate humoral
and adaptive immune responses, which is partly due to stimulation of multiple innate
immune responses by capsid and genome (Appledorn et al. 2008a,b, Hartman et al. 2008,
Barlan et al. 2011). Ad vectors have been successfully used to generate adaptive
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responses against antigens from rabies, cancer, HIV and malaria (Gabitzsch et al. 2009,
Xiang et al. 1996, Shott et al. 2008, Naslund et al. 2007).
Compared to other adjuvants, Ad vector approaches can promote stronger antigen
specific adaptive immune responses, including to malaria antigens (Rodrigues et al. 1997,
Shott et al. 2008, Bruna-Romero et al. 2004, Bruder et al. 2010). Ad expressing CSP can
induce equivalent antibody titers and an equivalent cellular response as RTS,S/AS01B
and does not require additional adjuvants (Shott et al. 2008). Importantly Ad based
malaria vaccines induce CD8+ T cell responses, which are important for protection
against pre-erythrocytic stages (Rodrigues et al. 1997, Rodrigues et al. 1998, BrunaRomero et al. 2008). Ad vectors have also been used to increase antibody titers to blood
stage malaria antigens. Ad expressing AMA-1 or APA-1 induces antibody titers
equivalent to recombinant protein with adjuvant (Bruder et al. 2010).
Limitations of Ad vectors include neutralizing antibodies to vectors due to preexisting immunity or homologous primary immunization. In human trials using primeboost with Ad expressing CSP and AMA-1, boost immunization was less immunogenic
than primary immunization and prime-boost did not protect against malaria challenge
(Tamminga et al. 2011, Sedagh et al. 2011). Pre-existing immunity to Ad5 is a concern in
Sub-Saharan Africa where over 50% of individuals have neutralizing antibody titers to
Ad5, which would weaken immune responses to Ad5 vectored antigens (Barouch et al.
2011, McCoy et al. 2007). To overcome this limitation, alternative Ad serotypes can be
used (Limbach and Richie 2009). Ad35 based CSP vaccines induce equivalent T and B
cell responses to CSP as Ad5 vectors and RTS,S/AS01B (Shott et al. 2008). Chimpanzee
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Ad should have the lowest levels of pre-existing immunity in human populations and
these vectors are also being investigated as alternatives to Ad5 (Reyes-Sandoval et al.
2008). Immunization with ChAd63 expressing Pfs25 followed by MVA expressing Pfs25
is as effective as Ad5/MVA prime-boost (Goodman et al. 2011).
Improving Ad vectors for TBV
My goal is to evaluate how immunization with different Ad vectors affects the
antibody response to EGF-like domains in Pfs25 and identify portions of the protein that
are highly associated with transmission blocking. To do this I will first purify EGF-like
domains from Pfs25 and use ELISA to assess domain specific titers in virus from mice
immunized with Ad vectors expressing Pfs25 or displaying epitopes from Pfs25. Using
epitope prediction tools, I will also develop new vectors with capsid displayed epitopes to
focus the antibody response to multiple highly immunogenic epitopes that are the target
of transmission blocking antibodies during infection. Finally, I will use Ad with capsid
displayed FliC to determine if I can improve the ability of our vectors to stimulate
antibody responses.
The results of this work will provide new information about how Ad vectors
induce antibody responses to target antigens. I will also have a better understanding of
how Ad vectors with capsid displayed epitopes can be used to focus antibody responses
to functionally relevant epitopes. Using FliC, I will learn how capsid modifications target
the adaptive immune response to antibody production.

CHAPTER TWO
MATERIALS AND METHODS
Cell Lines and Cell Culture
Our lab obtained HeLa and 293Trex cells from ATCC. We received 293β5 cells
from Glen Nemerow. We used HyClone tissue culture reagents. We maintained HeLa,
293β5 and 293Trex cells in Dulbecco Modified Eagle Medium (DMEM) with addition of
1mg/mL streptomycin, 100IU/mL penicillin, 0.25mg/mL amphotericin B, non-essential
amino acids, 2mM glutamine, 10mM HEPES buffer and 1mM sodium pyruvate. We
maintained 293Trex cells with 5μg/mL blasticidin from Sigma Aldrich.
Recombinant Virus Construction
We generated Ad5gfp as described by Wodrich et al. 2010. To generate Ad5Pfs25
and Ad5Pfs25exo we used a version of the AdEasy system described by He et al. 1998
and Luo et al. 2007. Using this system we inserted a shuttle vector containing the Pfs25
or Pfs25exo gene into an E1/E3 deleted Ad5 genome. We generated the Pfs25 gene using
Genescript and codon optimized it for expression in humans. To generate Pfs25exo, we
generated the codon optimized sequence for Pfs25 and removed the C terminal
transmembrane domain. To suppress Pfs25 and Pfs25exo expression during virus
propagation, we inserted the tet operator (TO) from pcDNA4/TO/mycHisA upstream of
the CMV promoter and propagated virus in 293Trex cells, which constitutively express
the Tet repressor (TetR). In this system, TetR binds TO and blocks transcription of the
Pfs25 or Pfs25exo transgene. Pfs25 expression prevents efficient recovery of virus
27
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because we found that Pfs25 expression decreased viral yields more than 10-fold. To
confirm that Pfs25exo expression is suppressed in 293Trex cells, we used IFA with Pfs25
antiserum. To confirm that Pfs25exo is expressed by our construct, we used IFA with 293
cells stained with Pfs25 antiserum.
I identified predicted B cell epitopes from Pfs25 using the ElliPro tool
(http://tools.immuneepitope.org/ellipro/). We generated AdCD using galK recombineering
as described by Warming et al. 2005. We created primers with the galK sequence flanked
by sequences homologous to regions to either side of the insert site in HVR1 or HVR5
and used these primers to amplify galK from a plasmid (pgalK), which our lab obtained
from the NCI BRB Preclinical Repository (NCI-FCRDC). Using homologous
recombination, we replaced target sites in HVR5 with galK and used positive selection on
minimal media plates with galactose to select successful recombinants. To replace galK
with sequences from Pfs25 we used homologous recombination with Pfs25 sequences
flanked by sequences homologous to the regions to either side of galK, which we
generated as gBlocks from IDT-DNA. To identify successful recombinants we used
negative selection on minimal media plates containing X-gal, which is converted to toxic
metabolites by cells that have retained galK. To confirm correct inserts, we used PCR
amplification of the hexon region and sequencing.
Virus Purification and Titering
We used 293Trex cells to propagate Ad5Pfs25exo and 293β5 cells to propagate
AdCD. After propagation, we purified virus using two rounds of cesium chloride
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centrifugation and dialysed virus in 40mM Tris, 150mM NaCl, 10% glycerol and 1mM
MgCl2 (pH 8.2) (Wiethoff et al. 2005). We determined virus concentration by Bradford,
where 1mg protein corresponds to 4x109 viral particles (Bio-Rad Laboratories, Inc.),
froze aliquots in liquid nitrogen and stored them at -80 °C. To determine viral titers of
AdCD, we serially diluted virus on HeLa cells and used flow cytometry to quantify GFP
expression. To determine titers of Ad5Pfs25 and Ad5Pfs25exo, we serially diluted virus
on HeLa cells and used IFA to detect hexon. To confirm expression of Pfs25exo, we used
IFA with Pfs25 anti-serum after treating cells with GolgiStop for 4 hours to prevent
protein secretion.
Reagents and Antibodies
For ELISA, we purchased 5x assay diluent (cat # 00-4202-56) and 1xTMB
substrate from eBioscience (cat # 00-4201-56). For detection of primary mouse antibody
we used HRP conjugated anti-mouse IgG from Abcam (ab97265). For protein
purification we used TALON Metal Affinity Resin from Clontech (cat # 635501). We
obtained the anti-Pfs25 antibodies from Kim Williamson (conformation specific: ID2,
conformation independent: 4B7).
ELISA
We coated high binding ELISA plates (Costar cat# 07-200-35) with Pfs25 or
purified domains from Pfs25 at 1μg/ml in coating buffer (Sodium Bicarbonate, pH 10)
shaking overnight at 4°C. The next day we washed plates 4 times with 200μl/well 1X
PBST (0.05% Tween) and blocked with 200μl/well 1x AD (eBioscience 00-4202-56) for
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1 hour. We washed the plates four times and added 100μl/well of serially diluted mouse
serum or monoclonal anti-Pfs25 antibody in 1x AD to plates for 2 hours. After 4 washes
we added a 100μl/well of secondary anti-mouse IgG diluted 1:2000 in 1x AD for 1 hour.
We washed plates 4 times and developed them using 50μl/well 1x TMB substrate. After
color change, we stopped the reaction with 25μl/well 1M sulfuric acid. We read plates
with a KC Junior plate reader at an optical density of 450nm. We determined endpoint
antibody titers (measured in ELISA units) using a dilution curve.
Mice and Immunizations
We used C57BL/6 mice (Jackson Laboratories cat# 000663) for all experiments.
The Institutional Animal Care and Use Committee of Loyola University Chicago
(Maywood, IL) reviewed all studies. We immunized mice at 6-12 weeks old by injection
in the left quadriceps. For primary immunization we immunized mice at 6-8 weeks of age
and euthanized mice and collected serum by cardiac puncture after 21 days. For boost
immunization experiments, we boost immunized 21 days after primary immunization and
euthanized mice after 21 days and collected serum by cardiac puncture. We used a
volume of 50μL for all injections.
For immunizations with Pfs25 protein, we used yeast produced Pfs25 from the
NIH adsorbed to aluminum hydroxide (alum) purchased as Alhydrogel (Invivogen cat#
21645-51-2). To prepare protein-alum for injection, we added 25 μL alum to 2.5 μg Pfs25
in a total volume of 50 μL. For all primary immunizations with virus we used 109 viral
particles. For secondary immunization with AdCD we used 1010 viral particles.

31
We collected blood from euthanized mice by cardiac puncture. To isolate serum,
we kept blood on ice for 1-4 hours and spun down red blood cells at 8000rpm for 5
minutes. We aliquoted supernatants, froze them in liquid nitrogen and stored them at 80°C.
Pfs25 Domain Synthesis and Purification
We used a previously developed codon optimized Pfs25 sequence to select
sequences encoding Pfs25 domains 1-4. For domain 4, we selected the sequence without
the transmembrane domain. For domain 1 we removed the membrane secretion signal
sequence. We ordered the domain sequences as gBlocks from IDT-DNA and ligated
them into the pGEMT-easy vector. We digested pGEMT-easy-Pfs25Dx with NdeI and
BamHI to free the Pfs25 domain sequence and ligated this fragment into protein
expression vector pET15b that had been digested with NdeI and BamHI. We confirmed
ligation by digesting pET15bPfs25Dx with NdeI and BamHI and using gel
electrophoresis to identify bands corresponding to the Dx sequences.
To express Pfs25D1-4 we transformed BL21 E. coli, which are optimized for
protein expression and grew cultures overnight in LB with ampicillin at 37⁰C. The next
day we diluted overnight cultures 1:20 in 500mL LB with ampicillin and grew them at
37⁰C until an OD600 of 0.6. We induced protein expression using 1mM IPTG for 4 hrs.
We harvested cells by centrifugation at 0⁰C. We performed all subsequent steps on ice or
at 0⁰C. To lyse cells we incubated the cell pellet with 40mL 1% triton X-100, 0.5mg/mL
lysozyme and 1:100 DNase in 50mM PBS per liter of culture. To prevent protein
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degradation we added 1:100 PMSF to all buffers. We solubilized the pellets in lysis
buffer and centrifuged lysate at 13,000xG for 15 min. Due to presence of protein in lysate
supernatant and reported presence in inclusion in bodies in pellet after lysis, we purified
both soluble and insoluble fractions.
We purified Pfs25 domains present in inclusion bodies according to the Pfs25
purification and refolding protocol developed by Kumar et al. 2014. To solubilize
inclusion bodies and denature misfolded proteins, we incubated pellets from cell lysate in
denaturation buffer (100mM tris, 8M urea, 1% BME) at 4⁰C overnight. After
solubilization, we loaded pellets onto 0.5mL TALON cobalt resin columns. We loaded
soluble Pfs25 directly onto columns and incubated with denaturation buffer overnight to
reduce misfolded disulfide bonds.
For on column refolding, we sequentially washed the column with 10mL
refolding buffer (100mM TrisCl, 500mM NaCl, 10% glycerol, 1mM imidazole, 0.5mM
GSSG and 5mM GSH) containing decreasing amounts of urea from 8M to 0M,
incubating for 1hr at each step. To elute protein we used 150mM imidazole and dialyzed
protein in a 3.5kD dialysis cassette in PBS with 1% glycerol.
To purify protein for refolding by dilution, we loaded supernatant from BL21 on
0.5mL TALON cobalt resin columns. We washed columns once with 10 mL Wash
Buffer 1 (50mM phosphate, 500mM NaCl, 1mM imidazole and 1% triton X-100) and
with 10mL Wash Buffer 2 (50mM phosphate, 500mM NaCl and 1mM imidazole) in 1
mL increments. To elute protein we used 150mM imidazole and dialyzed protein in a
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3.5kD dialysis cassette in PBS with 1% glycerol. We precipitated protein using
trichloroacetic acid (dilute TCA to 10% in sample, precipitate overnight at -20⁰, spin
sample, wash with acetone and evaporate acetone) and resuspended precipitated protein
in denaturation buffer. After resuspending protein in denaturation buffer to achieve a
concentration of 2µL, we diluted the solution 1:20 in 100mM tris with 0.5mM GSSG and
5mM GSH. After dilution, we dialyzed samples in 3.5kD dialysis cassettes in PBS with
1% glycerol.
We determined concentration of protein by Bradford in all cases and used tris
tricine gel electrophoresis (10% separating, 4% stacking) followed by Coomassie stain to
confirm sample purity and Western Blot with Pfs25 anti-serum to confirm presence of
Pfs25 domains. We used ELISA with conformation dependent antibody ID2 to assess
refolding success for D3 and conformation independent antibody 4B7 to confirm that
peptide is D3.
SDS-PAGE and Western Blots
To determine location of Pfs25 domains during purification and assess purity of
refolded domains, we loaded samples from each step of purification onto tris-tricine gels
consisting of 4% stacking gel and 10% resolving gel and after electrophoresis detected
proteins by Western blot. For Western blots we used yeast purified recombinant Pfs25
from the NIH as a positive control. WE detected His tagged domains using polyclonal
anti-Pfs25 serum diluted 1:250 or monoclonal antibody to 6X-His. For detection of
primary antibody we used HRP-conjugates anti-ms IgG at a concentration of 1:1000.
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Statistics
We assessed statistical significance (p<0.05) using Student’s T Test when
comparing two groups. Data is presented as mean +/- SEM.

CHAPTER THREE
RESULTS
EGF domains from Pfs25 are expressed in soluble fraction of BL21 E. coli lysates
Pfs25 is composed of four EGF-like domains. In its native conformation on the
parasite surface, Pfs25 domains 2 and 3 are thought to be the most surface exposed and in
a previous study, domain 2 was most highly associated with transmission blocking
antibodies (Figure 3, Stowers et al. 2000). To bind to Pfs25 and block transmission,
antibodies must be directed at epitopes near sites of interaction with host receptors.
Immunizations that direct the antibody response to domains 2 and 3 should be better at
blocking transmission than strategies that target portions of Pfs25 more distal from these
host receptor interacting sites or which are not accessible on the parasite surface. To
compare domain specific antibody responses to immunization with different Ad vectors, I
first had to purify and refold domains 1-4 from Pfs25.
Kumar et al. 2014 reported that Pfs25 expressed in E. coli was present in
insoluble cytoplasmic aggregates called inclusion bodies that they isolated by
centrifugation after lysis. These aggregates often form during expression of recombinant
proteins in E. coli, especially at high levels of expression and are a result of
intermolecular interactions of misfolded protein (Palmer and Wingfield 2004). However,
expression of smaller fragments of a protein could affect aggregation and reduce
inclusion body formation.
35
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To determine if EGF domain 3 from Pfs25 is expressed as insoluble aggregates in
E. coli, I grew cultures of BL21 E. coli transformed with pET15b-domain 3 to an OD600
of 0.6. After inducing protein expression with IPTG for 4 hours, I pelleted and lysed
cells. I loaded supernatant from centrifuged lysate and cell debris in non-denaturing
buffer on a tris tricine gel and transferred the band to a nitrocellulose membrane. To
detect domain 3, I probed the membrane with an antibody against 6X-His. Unlike Pfs25,
domain 3 is soluble, however, based on lack of a distinct band the peptide is most likely
forming soluble aggregates (Figure 4). Aggregation is most likely due to intermolecular
interactions between misfolded proteins and could be due to disulfide bonds, which
would remain intact unless denatured. These aggregates appear to be soluble for domain
3.
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Figure 4: Expression of domain 3 in E. coli. I lysed cells in lysis buffer and pelleted cell
debris. I loaded supernatant from lysate and resuspended pellet onto a tris-tricine gel
under non-denaturing conditions. After transferring to a nitrocellulose membrane, I
detected domain 3 using an antibody against the 6X-His tag present on the peptide.
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Refolding of domains from Pfs25
Optimal refolding protocols vary even for similar proteins and screening several
protocols is usually necessary to identify the most optimal refolding strategy. When
refolding proteins that contain disulfide bonds, the first step is denaturing the protein and
reducing disulfide bonds, for which I chose urea and β-ME. Once protein is denatured
and reduced, it can be refolded by removing the denaturing reagent, urea, in the presence
of a redox system. A mixture of reduced and oxidized glutathione is the most commonly
used redox couple. This allows disulfide bonds to reshuffle until they reach the desired
conformation. On column refolding allows more time for reshuffling of bonds as the
concentration of urea slowly decreases but also leaves the protein more prone to
aggregation at intermediate concentrations of urea. Alternatively, rapid dilution in a
solution that contains GSH:GSSG but no urea prevents long periods of exposure to
aggregation prone conditions but provides less time for refolding. Protein concentration is
another important consideration because aggregation occurs more rapidly at high
concentrations. The range of 10-100µg/mL is ideal to preserve the balance between
refolding and aggregation (Mamathambika and Bardwell 2008).
I first attempted refolding of domain 3 because I have a conformation specific
antibody to an epitope in D3, which I can use to quickly assess folding success using
ELISA. I expressed domain 3 in BL21 E. coli and collected lysates. I loaded lysates onto
a TALON Cobalt affinity column and refolded domain 3 on the column, or purified it on
the column and refolded by dilution. I determined concentration by Bradford assay.
Concentrations for several purifications of domain 3 ranged from 74.7-99.4 ng/µL. To
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assess purity of refolded protein, I loaded 0.5µg on a tris tricine gel and used Coomassie
dye to detect proteins. Domain 3 peptides from both purification methods did not contain
contaminating protein (Figure 5). These results indicate that I successfully isolated
domain 3 and that the samples did not contain detectable protein contaminants.
To confirm that the purified protein is domain 3, I coated ELISA plates with
equimolar amounts of domain 3 and Pfs25 that is presumed to be correctly folded
(Kaslow et al. 1992) and probed with the conformation independent transmission
blocking antibody 4B7. Titers for both purified domains 3 were similar to those for Pfs25
(Figure 6A). This indicates that the purified peptide is domain 3 and that 4B7 titers
accurately reflect the expected ratio of coated proteins. To determine if domain 3 is
correctly folded, I coated plates with purified domain 3 or Pfs25 and probed with the
conformation dependent transmission-blocking antibody ID2. ELISA titers against either
refolded domain 3 preparation were significantly lower than those observed for full
length Pfs25 (Figure 6B). This suggests that the ID2 epitope was misfolded in domain 3
compared to full length Pfs25.
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Figure 5: Purified and refolded domain 3. I loaded 0.5µg of domain 3 purified and
refolded on column and domain 3 purified on column and refolded by dilution onto a tris
tricine gel. I loaded samples under reducing conditions.
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Figure 6: ELISA titers on plates coated with equimolar amounts of Pfs25, D3 refolded on
column and D3 refolded by dilution detected using conformation independent
monoclonal antibody 4B7 (A) or conformation dependent monoclonal antibody ID2 (B).
Titers are shown on an inverse log scale.
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Pfs25 expression by cells infected with Ad5Pfs25exo
Goodman et al. 2011 immunized mice with Ad vectors encoding a secreted form
of Pfs25. Although this approach generated high titers of transmission blocking
antibodies, displaying Pfs25 on the cell surface could more closely mimic its native state
and generate a higher quality transmission blocking antibody response focused on surface
accessible epitopes. In mice immunized with yeast purified Pfs25 domains, serum from
immunization with domain 2 was most effective at blocking transmission even at low
antibody titers (Stowers et al. 2000). Domains 2 and 3 contain predicted B cell epitopes
and contain surface loops that are solvent exposed based on modeling. Targeting these
two domains could lead to a higher quality transmission blocking response.
Ad5Pfs25exo encodes a form of Pfs25 with no transmembrane domain and is
therefore secreted by infected cells. I used IF to confirm that Ad5Pfs25exo infected cells
express Pfs25 Figure 7). I treated Ad5Pfs25exo infected 293β5 cells with Golgi Stop for
four hours to retain Pfs25 in cells and fixed them in 3.7% PFA. To visualize Pfs25, I
probed with a monoclonal antibody against Pfs25. Infected cells stained positive for
intracellular Pfs25. This indicates that cells infected with Ad5Pfs25exo express the
transgene.
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Figure 7: IFA of 293β5 cells infected with Ad5Pfs25exo. I infected 293β cells with
Ad5Pfs25exo overnight. To prevent secretion of Pfs25, I treated cells with GolgiStop for
four hours before I fixed infected cells in 3.7% PFA and stained them with a monoclonal
antibody against Pfs25 (4B7). (A) cells infected with Ad5Pfs25 as a positive control. (B)
uninfected cells. Two different images of cells infected with Ad5Pfs25exo shown with
DAPI staining (C) and without DAPI staining (D).
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Immunization with Ad5Pfs25exo generates lower antibody titers compared to
immunization with Ad5Pfs25
To determine if membrane bound Pfs25 elicits similar antibody titers to whole
Pfs25 as soluble Pfs25, I immunized mice with Pfs25-alum, Ad5Pfs25 and Ad5Pfs25exo
and collected serum after 21 days. Ad5Pfs25exo expresses a Pfs25 transgene with
transmembrane domain removed. Mice immunized with Ad5Pfs25exo develop lower
antibody titers than mice immunized with Ad5Pfs25, which indicates that membrane
bound Pfs25 is a superior immunogen to soluble Pfs25 (Figure 8). Pfs25alum generates
the lowest antibody titers. These results support using Ad5Pfs25 for primary
immunization.
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Figure 8: Antibody titers by ELISA in serum from mice immunized with Pfs25-alum,
Ad5Pfs25 and Ad5Pfs25exo. I immunized mice with 2.5µg protein or 109 viral particles
and collected serum after 21 days.
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Immunization with Ad5Pfs25exo targets different EGF like domains than Ad5Pfs25
Mice immunized with soluble recombinant Pfs25 develop similar antibody titers
to each domain (Stowers et al. 2000). I expected that membrane bound Pfs25 would alter
the balance of antibody response to domains that are more surface accessible and
therefore more likely to be important for transmission blocking. In contrast, I expected
soluble Pfs25 delivered as Ad5Pfs25exo would activate more cells reactive against
domains that are not normally accessible on the parasite surface. In particular domain 2
has been associated with the highest level of transmission blocking and domains 2 and 3
contain the most likely predicted B cell epitopes (Stowers et al. 2000). A TBV that
preferentially targets these domains would be more effective than a vaccine that targets
epitopes that are not surface accessible. I purified and refolded domains 1-4 according to
the on column purification and refolding by dilution protocol used for domain 3.
To assess which Pfs25 domains are targeted by immunization with Ad5Pfs25 or
Ad5Pfs25exo, I coated plates with domains 1-4 and probed with serum from immunized
mice. Ad5Pfs25 and Ad5Pfs25exo elicit equivalent titers of antibodies against domain 3,
which contains the best predicted B cell epitopes. Additionally, Ad5Pfs25 serum contains
high titers to domain 1 (Figure 9).
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Figure 9: Domain specific antibody titers by ELISA using serum from mice immunized
with Ad5Pfs25 or Ad5Pfs25exo. I immunized mice with 109 viral particles and collected
serum after 21 days. For ELISA, I coated plates with 25ng of Pfs25 domains and probed
with serum from immunized mice.
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Domain specific antibody response to AdCD vectors
Mice immunized with individual yeast purified domains followed by boost with
full length Pfs25 develop similar titers to all 4 domains despite low domain specific titers
after primary immunization with domains 3 and 4 (Stowers et al. 2000). This indicates
that antigen primed cells to each domain can be boosted even if prime immunization
generates a weak domain specific antibody response. To generate the most effective
TBV, we need to target Pfs25 epitopes that are surface exposed and can elicit the
strongest B cell response.
I expected immunizing mice with vectors that display epitopes from Pfs25 to
focus the antibody response to the domain where the epitope is found. This would
generate a higher quality transmission blocking response by targeting biologically
relevant portions of Pfs25. I used serum from mice immunized with Pfs25-alum and
boost immunized with Pfs25-alum, Ad5HVR5D2 or Ad5HVR5D3 for ELISA on plates
coated with domains 1-4. I used Pfs25-alum for primary immunization instead of
Ad5Pfs25 to avoid generating neutralizing antibodies to the vector, which could reduce
the efficacy of AdCD vectors. Ad5HVR5D3 increases antibody titers to domain 3 relative
to both Ad5HVR5D2 and Ad5Pfs25-alum, suggesting that this may be a means to better
focus antibody responses to transmission blocking epitopes (Figure 10). Unexpectedly,
Ad5HVR5D2 did not increase titers to domain 2 relative to the other sera tested.
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Figure 10: Domain specific ELISA titers for serum from mice primed with Pfs25-alum
and boost immunized with Pfs25-alum, Ad5HVR5D2 or Ad5HVR5D3. Protein
immunization was with 2.5µg Pfs25 and virus immunizations were with 1010 viral
particles.
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Transmission blocking activity of serum from mice immunized with AdCD
I expected immunization with AdCD to focus the antibody response against Pfs25
to epitopes that are surface exposed and highly correlated with transmission blocking
activity. Although Ad5Pfs25/AdCD immunized mice develop lower antibody titers than
mice boost immunized with Pfs25-alum, the antibody response should be more focused
to capsid displayed epitopes. If these epitopes are the target of transmission blocking
antibodies, then I expect to see a potent transmission blocking response even with lower
antibody titers.
I assessed transmission blocking activity using SMFA, where mosquitoes feed on
serum from immunized mice mixed with P. falciparum gametocytes. SMFA was
performed by K. Miura and C. Long at the NIH. At the highest dilution used (1:20),
serum from mice immunized with Ad5Pfs25 and boost immunized with Pfs25-alum or
AdCD blocked formation of oocysts (Figure 11). Serum from mice immunized with
Pfs25-alum/Pfs25-alum did not inhibit parasite transmission more than serum from mice
immunized with empty Ad5 vector.
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Figure 11: Transmission blocking activity of serum from mice immunized with
Ad5Pfs25/AdCD compared to Ad5Pfs25/Pfs25-alum and Pfs25-alum/Pfs25-alum
measured by standard membrane feeding assay. Serum was diluted 1:20. 4B7 is a
monoclonal antibody against an epitope in Pfs25 used as a control.
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A new epitope from Pfs25 domain 3
So far I have created vectors that display two epitopes, D2 and D3. However,
these only represent two surface exposed loops on Pfs25 and are not the only potential
epitopes in domains 2 and 3 (Figure 3). Eventually, I could use a combination of AdCD
displaying different epitopes for boost immunization to focus the antibody response to
epitopes associated with transmission blocking.
I used ElliPro B cell epitope prediction software to identify a new epitope to use
in AdCD vectors, D3C. D3C is an epitope in domain 3 that is the second most likely
predicted B cell epitope in Pfs25 after D3 and is found on the second loop in Pfs25
domain 3 (Figure 3). Ad5HVR5D3C PF has similar viral titers to other AdCD, which
indicates that it is able to effectively replicate. Antibody titers by ELISA to serum from
mice immunized with Ad5Pfs25 and boost immunized with Ad5HVR5D3C PF are
comparable to mice immunized with Ad5HVR5D3 with or without PF and lower than for
mice immunized with Ad5HVR5D2 (Figure 12).
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Figure 12: Comparison of antibody titers by ELISA for serum from mice immunized with
Ad5Pfs25/Pfs25alum and four AdCD vectors.

54
AdCD vectors with FliC do not induce higher antibody titers than AdCD vectors
without FliC
Flagellin (FliC) has previously been used as an adjuvant to increase antibody
titers and is a potent activator of multiple innate and adaptive immune pathways (Mizel
and Bates 2010). I have developed Ad vectors with a C-terminal peptide from FliC
appended to pIX and capsid displayed Pfs25 epitopes. I expected that vectors with FliC
would elicit higher antibody titers than vectors without FliC. I previously made AdCD
displaying the D3 epitope in HVR5 and compared them to Ad5HVR5D3 PF.
I boost immunized Ad5Pfs25 primed mice with Ad5HVR5D3 with or without
FliC attached to pIX. I collected serum after 21 days and used it to probe ELISA plates
coated with Pfs25. I did not detect a significant difference between serum from mice
immunized with AdCD or AdCDPF (Figure 13). This indicates that capsid displayed FliC
does not improve the antibody response to D3 displayed in HVR5. To determine if boost
immunization with AdCD PF affects titers to Ad5 capsid, I coated ELISA plates with Ad5
capsid and probed with serum from immunized mice. Mice immunized with vectors that
contain PF develop higher antibody titers compared to vectors with wild type pIX (Figure
14).
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Figure 13: Antibody titers by ELISA for serum from mice immunized with 109 viral
particles Ad5Pfs25 and boost immunized with 1010 viral particles Ad5HVR5D3 or
Ad5HVR5D3 PF. I collected serum 21 days after boost immunization.
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Figure 14: Antibody titers to Ad5 capsid for mice immunized with 109 viral particles
Ad5Pfs25 and boost immunized with 1010 viral particles Ad5HVR5D3 or Ad5HVR5D3
PF. I collected serum 21 days after boost immunization.

CHAPTER FOUR
DISCUSSION
Despite decreasing incidence and mortality, malaria due to Plasmodium
falciparum continues to be a problem and eradication requires ongoing efforts. As drug
resistance spreads and mosquitoes become resistant to insecticides, the need for new
drugs and vaccines becomes more urgent to achieve the current goal of complete
eradication. Several vaccine candidates have been identified to target multiple stages in
the lifecycle of P. falciparum, including transmission blocking vaccines that target the
sexual stages. Of the sexual stage antigens, Pfs25 has been studied the most and has been
used in clinical trials with various adjuvants. Antibodies to Pfs25 have also been found to
be more effective at blocking transmission than antibodies to any other P. falciparum
protein. I have developed Ad vectors to deliver Pfs25 or selected epitopes from Pfs25 and
propose Ad vectors as the best adjuvant for creating an effective TBV against Pfs25.
My goal in this work was two-fold. First, I wanted to determine whether I could
better focus antibody responses to transmission blocking antigens so that transmission
blocking antibody titers would be higher. Second, I wanted to determine whether
enhancing the immunogenicity of adenovirus vaccine vectors could further increase
transmission blocking antibody titers to Pfs25.
Refolding of Pfs25 D3
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Using ID2, I did not detect significantly elevated titers to domain 3 by ELISA.
This indicates that the epitope for ID2 is not folded correctly but other portions of the
domain could be folded correctly. In previous work, ID2 was used to monitor success in
refolding whole Pfs25 before proceeding to more accurate methods (Kumar et al. 2014).
In addition to assessment using ID2, I could use circular dichroism spectropolarimetry to
assess secondary structure and eventually I would use NMR to assess the complete
structure, which would provide more information than only assessing one epitope.
Protein refolding is a complicated process and ideal conditions vary even for
similar proteins. This is particularly true for cysteine rich proteins with disulfide bonds
that are essential to their structure, such as EGF proteins. Despite many successful
purifications of recombinant proteins from E. coli, we are unable to accurately predict the
best refolding protocol for a given protein and refolding attempts usually involve trials
with many different protocols and reagents. The refolding conditions that worked for
whole Pfs25 may not be effective for refolding individual domains. Future attempts to
refold D3 should use varying concentrations of denaturing agent because overly
aggressive denaturation of peptide could reduce the success of refolding. Additionally, I
could vary the time protein is allowed to refold to allow more time for shuffling of
disulfide bonds until they assume the proper arrangement. If I removed urea too rapidly
at a stage where disulfide bonds were beginning to correctly form then I might have
missed a critical point in refolding. I could also try different redox couples or change the
GSH:GSSG ratio, which is important because these reagents stabilize intermediate forms
of cysteine during formation of disulfide bonds.
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Domain specific ELISA
I only assessed the refolding of domain 3 but I purified all four domains using the
most efficient protocol I tried. Although I used these domains for ELISA, I do not know
how efficiently my protocol refolded them. ID2 is one of two purified monoclonal
antibodies to Pfs25 available and is the only conformation dependent one. Due to the
variability in refolding conditions for different proteins, any of the other domains could
have been refolded more or less efficiently than the others using the same protocol. I
could assess the refolding of the other domains using NMR. However, even with this
variability, domain specific titers to partially correct peptides can provide information
about the differences between immunizations.
Despite uncertainty in the proper folding of the individual Pfs25 EGF domains,
antibodies to Pfs25 and Pfs25exo bind domain 3 equally. These similar titers to D3 are
not surprising because D3 contains the two most likely predicted B cell epitopes in Pfs25.
The major difference in domain specificities between antisera from Ad5Pfs25 and
Ad5Pfs25exo immunized mice were in binding to domain 1. I did not assess transmission
blocking activity of Ad5Pfs25exo serum and therefore I cannot say whether increased
titers to domain 1 in mice immunized with Ad5Pfs25 are related to transmission
blocking. According to Stowers et al. 2000, high titers of antibodies to domain 1 correlate
with transmission blocking activity but only domain 2 immunized serum blocked
transmission at low antibody titers. Based on this, the higher response to domain 1 could
be relevant for transmission blocking.
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When I assessed the targeting of domain 2 or domain 3 using capsid displayed
epitopes from each domain, I found that Ad5HVR5D3 increased antibody titers to
domain 3 but Ad5HVR5D2 did not increase antibody titers to domain 2 and the overall
titers for each domain were lower for Ad5HVR5D2. This is unexpected because ELISA
using plates coated with correctly folded Pfs25 shows that Ad5HVR5D2 elicits similar
antibody titers to the whole protein as Ad5HVR5D3. This could be indicative of the
limitations of my most likely misfolded proteins, which might not be recognized by
serum antibodies. Alternatively, if the D2 epitope is not displayed in a native
conformation in hexon, this could affect the effectiveness of targeting the antibody
response to that epitope in the context of native protein. Based on B cell epitope
prediction, the D2 epitope is the most likely surface accessible B cell epitope in Pfs25 but
this could be incorrect. Immunization with Ad5HVR5D3 increases antibody titers to
domain 3 relative to Pfs25-alum immunization, which suggests that this vector
successfully shifts the antibody response to the D3 epitope. If domain 3 was correctly
folded, I expect that titers would be even higher.
Creating new AdCD vectors
Although I successfully purified a vector displaying a new epitope from domain
3, Ad5HVR5D3C, I also unsuccessfully tried to propagate a virus displaying another
epitope from domain 2, Ad5HVR5D2B, and a virus displaying a modified version of the
D3 epitope, Ad5HVR5D3B, based on B cell epitope prediction. This shows the
limitations of displaying certain sequences on the capsid surface. The unsuccessful
viruses could not be efficiently propagated, which suggests that the inserted sequences
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interfere with proper capsid assembly. The best solution to this problem would be to
identify predictors of success when inserting epitopes into the capsid and this would be a
major advancement in our knowledge of manipulating Ad vectors. If I could identify
parameters that predict success for insertion into hexon, then I could more effectively
design epitopes for AdCD that do not interfere with virus propagation.
I designed new AdCD using SwissProt modeling software to measure the distance
between the first and last residues of the Pfs25 loop to replace a loop of similar width in
HVR5. Additionally, I lined up cysteines that form disulfide bonds. I expected that
preserving disulfide bonds would add support to the structure and help with correct
display. Only one vector out of three grew, which suggests that predicting size by
modeling is not sufficient to predict success. Leaving disulfide bonds also did not
improve success at generating virus. This could be due to unfavorable constraints
imposed by having a disulfide bond that might interfere with capsid assembly in some
AdCD. In this case the D3C loop might allow a conformation that is more favorable for
capsid assembly compared to D3B and D2B. This could be resolved by omitting the
cysteines in those loops, which could increase flexibility at the point of contact with
HVR5.
Focusing the antibody response to transmission blocking epitopes
Domain specific ELISA did not support the ability of Ad5HVR5D2 to target
transmission blocking epitopes but SMFA data and anti-Pfs25 ELISA data suggest that
this vector, as well as Ad5HVR5D3 improves the quality of the transmission blocking
response. Although AdCD boost immunization generates several-fold lower ELISA titers
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than boost immunization with Pfs25-alum, serum from mice immunized with
Ad5Pfs25/Ad5CD blocks P. falciparum transmission as well as serum from mice
immunized with Ad5Pfs25/Pfs25-alum. This indicates that AdCD generate a more potent,
but less abundant transmission blocking antibody response. For a more accurate
comparison of the most effective immunizations, I would need to dilute serum used for
SMFA until transmission is no longer blocked, since at a 1:20 dilution, all sera
completely blocked transmission.
Future experiments should test the efficacy of immunizing with a combination of
AdCD to target several surface exposed epitopes. I expect that using multiple AdCD would
improve the transmission blocking activity of serum from immunized mice by focusing
the response to multiple epitopes. This approach would also reduce the likelihood of
vaccine resistant strains developing by not putting selective pressure on a single epitope.
Additionally, I would assess whether using certain epitopes produces more long lived
plasma cells. This is an important predictor of vaccine success because a TBV targeting
Pfs25 cannot be successful without persistent antibody secretion long after immunization.
Heterologous prime boost immunization with different Ad serotypes could improve the
antibody response by reducing competition between activation of Pfs25 and capsid
reactive memory cells.
Effect of capsid displayed FliC on antibody response to AdCD vectors
FliC has been used as an adjuvant to increase antibody titers to antigen. In
previous studies, researchers have administered FliC fused to antigen and as a mixture of
antigen and FliC (Girard et al. 2011, Taylor et al. 2011). Both strategies result in higher
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antibody titers, increased activation of a TH2 helper T cell response and increased
retention of antigen in draining lymph nodes. I expected that by attaching a domain of
FliC to Ad5 capsid to selectively activate the inflammasome and not TLR5, I would also
increase antibody titers to capsid displayed antigen. However, I did not see a difference in
antibody response to the Pfs25 epitope displayed on the capsid (Figure 13). I did,
however, observe a tremendous increase in the antibody response to the rest of the Ad5
capsid (Figure 14).
Since Ad proteins outnumber the single Pfs25 epitopes, I expect that after priming
immunization has generated a response to capsid and Pfs25, boost immunization with an
Ad vector of the same serotype would expand mostly cells reactive against capsid. This
could deplete extra resources and reduce the expansion of memory B cells reactive to the
Pfs25 epitope. In this case the effect of FliC is evident when I look at anti capsid titers. I
could overcome this by using a different serotype Ad that would not contain many
overlapping epitopes with Ad5. Priming with this vector and boosting with Ad5CD might
favor expansion of B cells reactive to capsid displayed Pfs25 epitopes over anti-capsid
cells.
Concluding remarks
Although I was unable to purify and refold EGF like domains from Pfs25, I tested
protocols that could be modified in the future to properly refold the peptides by changing
the reaction conditions. Using these peptides I saw some differences in domain specific
responses to Pfs25 but could only draw limited conclusions for this, especially using
Ad5Pfs25exo. Ad5HVR5D3 appears to focus the antibody response to domain 3 using
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my assay, unlike Ad5HVR5D2 and domain 2. Although our PF vectors did not enhance
the antibody response to Pfs25, this does not mean that FliC is not effective in
conjunction with Ad vectors and I would investigate other methods of delivering FliC
with Ad vectors. SMFA data provides the strongest support for using AdCD vectors to
focus the antibody response to certain Pfs25 epitopes and new epitopes should be
identified that are compatible with insertion into hexon.
An effective TBV for P. falciparum would improve our ability to eradicate
malaria and would be useful in conjunction with vaccines that target other lifecycle
stages but are not 100% effective, such as RTS,S. This combination would protect
individuals but in cases where gametocytes develop the TBV component would provide a
major public health benefit by breaking the transmission cycle.
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